CEBPB and Hepatic fibrosis: We graded the coded liver samples with the standard 0 to 4 METAVIR clinical system [18], and found that after CCl4 treatment, all C/EBPβ+/+ mice had severe liver fibrosis (grade 4; n: 12), while all C/EBPβ-Ala217 mice had minimal or no liver fibrosis (grade 0; n: 6; grade 1; n: 6) (P<0.0001) (Figure 1A).